Uwe Zangemeister-Wittke
Overview
Explore the profile of Uwe Zangemeister-Wittke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1349
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wojtalla A, Fischer B, Kotelevets N, Mauri F, Sobek J, Rehrauer H, et al.
Clin Cancer Res
. 2025 Feb;
31(4):787.
PMID: 39957402
No abstract available.
2.
Merten H, Brandl F, Zimmermann M, Schaefer J, Irpinio L, Sand K, et al.
Eur J Pharm Biopharm
. 2021 Jul;
167:104-113.
PMID: 34303832
Serum albumin shows slow clearance from circulation due to neonatal Fc receptor (FcRn)-mediated recycling and has been used for half-life extension. We report here fusions to a high-affinity DARPin, binding...
3.
Brandl F, Busslinger S, Zangemeister-Wittke U, Pluckthun A
J Control Release
. 2020 Aug;
327:186-197.
PMID: 32768630
Despite some approvals of antibody-drug conjugates for cancer therapy, their clinical success rate is unsatisfactory because of very small therapeutic windows, influenced by on-target and off-target toxicities of conjugate and...
4.
Schwalm S, Erhardt M, Romer I, Pfeilschifter J, Zangemeister-Wittke U, Huwiler A
Int J Mol Sci
. 2020 Feb;
21(4).
PMID: 32092937
Ceramide kinase (CerK) is a lipid kinase that converts the proapoptotic ceramide to ceramide 1-phosphate, which has been proposed to have pro-malignant properties and regulate cell responses such as proliferation,...
5.
Merten H, Schaefer J, Brandl F, Zangemeister-Wittke U, Pluckthun A
Methods Mol Biol
. 2019 Jul;
2033:253-273.
PMID: 31332759
For biomedical applications, proteins may require conjugation to small and large molecules. Typical examples are dyes for imaging, cytotoxic effector molecules for cell killing, or half-life extension modules for optimized...
6.
Brandl F, Merten H, Zimmermann M, Behe M, Zangemeister-Wittke U, Pluckthun A
J Control Release
. 2019 Jun;
307:379-392.
PMID: 31252038
Alternative non-IgG binding proteins developed for therapy are small in size and, thus, are rapidly cleared from the circulation by renal filtration. To avoid repeated injection or continuous infusion for...
7.
Lorenzer C, Streussnig S, Tot E, Winkler A, Merten H, Brandl F, et al.
Eur J Pharm Biopharm
. 2019 May;
141:37-50.
PMID: 31103742
Specific cell targeting and efficient intracellular delivery are major hurdles for the widespread therapeutic use of nucleic acid technologies, particularly siRNA mediated gene silencing. To enable receptor-mediated cell-specific targeting, we...
8.
Blanchard O, Stepanovska B, Starck M, Erhardt M, Romer I, Heringdorf D, et al.
Int J Mol Sci
. 2018 May;
19(5).
PMID: 29772789
Sphingosine kinase (SK) catalyses the formation of sphingosine 1-phosphate (S1P), which acts as a key regulator of inflammatory and fibrotic reactions, mainly via S1P receptor activation. Here, we show that...
9.
Huwiler A, Zangemeister-Wittke U
Pharmacol Ther
. 2017 Nov;
185:34-49.
PMID: 29127024
The immunomodulatory drug fingolimod (FTY720, Gilenya) was approved for oral treatment of relapsing-remitting multiple sclerosis, due to its impressive efficacy and good tolerability. Pharmacologically, it acts as an unselective agonist...
10.
Graumann R, Di Capua G, Oyarzun J, Vasquez M, Liao C, Branes J, et al.
PLoS One
. 2017 May;
12(5):e0177244.
PMID: 28472127
Teneurins are a family of highly conserved pair-rule proteins involved in morphogenesis and development of the central nervous system. Their function in adult tissues and in disease is largely unknown....